Regeneron Pharmaceuticals Inc. played up the potential for building a franchise around wet AMD drug Eylea, including new indications and co-formulations, after reporting better-than-expected fourth-quarter sales.
In a preliminary report on the fourth quarter, the company reported Jan. 14 that Eylea (aflibercept) posted U.S. sales of...